• In July 2026, Krystal Biotech disclosed in a U.S. patent filing response that a single neurotrophic keratitis patient treated with its investigational gene therapy KB801 in a discontinued study experienced complete closure of a persistent corneal epithelial defect, while emphasizing no safety concerns and that no efficacy conclusions should be drawn from this isolated case.
• At the same time, Krystal Biotech was moved from the small-cap focused S&P 600 into the mid-cap S&P 400 and its health care and biotechnology sub-indices, potentially broadening its exposure to index-linked investors just as interest in its ophthalmology pipeline candidate KB801 intensifies.
• We’ll now examine how the KB801 single-patient disclosure, alongside Krystal’s shift into S&P 400 indices, may influence its investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe that VYJUVEK can keep funding a broader gene therapy platform while new programs like KB801 eventually diversify revenue. The KB801 single patient disclosure is not clinically decisive, so the pivotal trial remains the key near term catalyst, while reliance on VYJUVEK and reimbursement progress in Europe and Japan still looks like the central business risk.

The most relevant recent development alongside the KB801 update is Krystal’s move into the S&P 400 and its health care and biotechnology sub indices. This change could increase visibility and index linked ownership just as attention on ophthalmology and other pipeline assets grows, potentially amplifying market reactions to upcoming KB801 pivotal data and any shifts in VYJUVEK’s revenue trajectory.

Yet behind the KB801 excitement, investors should also be aware of the ongoing “waviness” in VYJUVEK sales and what that could mean for...

Krystal Biotech's narrative projects $1.0 billion revenue and $552.3 million earnings by 2029.

Uncover how Krystal Biotech's forecasts yield a $361.67 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$1.4 billion of revenue and nearly US$950 million of earnings by 2029, so this new KB801 and index news could either reinforce that bullish view or prompt revisions, depending on how you weigh it against the risk that pipeline diversification may not arrive as quickly as hoped.

Explore 5 other fair value estimates on Krystal Biotech - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 55 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.